Current therapies and new developments in NASH
Jean‐François Dufour(Universidad Iberoamericana), Shira Zelber‐Sagi(Haifa Medical Center)
Cited by 194
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence
|World Journal of Gastroenterology|2011|299
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary
|Diabetologia|2024|150
A global research priority agenda to advance public health responses to fatty liver disease
|Journal of Hepatology|2023|132